Apple Inc. (AAPL.US) is reported to prioritize the release of high-end iPhone models in 2026 to address the challenge of memory shortages.
According to informed sources, due to marketing strategy adjustments and supply chain constraints, Apple Inc. (AAPL.US) is prioritizing the production and shipment of the three highest-end models of iPhone for 2026, while delaying the launch plans for its standard version models.
According to informed sources, due to adjustments in marketing strategy and supply chain restrictions, Apple Inc. (AAPL.US) is prioritizing the production and shipment of the three highest-end iPhone models for 2026, while postponing the launch plans for its standard models.
It is reported that the American tech giant will focus its resources on launching its first foldable screen iPhone and two flagship models with upgraded cameras and larger screens in the second half of the year, while the standard iPhone 18 is currently planned for release in the first half of 2027.
Against the backdrop of rising memory chip and material costs, this adjustment aims to optimize resource allocation, maximize revenue and profit through high-end devices, and reduce production risks associated with the more complex processes of Apple Inc.'s first foldable device.
A senior executive from an iPhone supplier directly involved in the plan stated, "The smoothness of the supply chain is one of the key challenges this year, and adjustments in marketing strategy have also influenced the decision to prioritize high-end models."
Apple Inc. announced its first quarter earnings report this past Thursday, surpassing Wall Street expectations, mainly driven by strong iPhone demand and significant recovery in the Chinese market. CEO Tim Cook stated that the demand for the latest phones in the market is "amazing."
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


